Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2018 Aug;10(8):4689-4693.
doi: 10.21037/jtd.2018.07.120.

Tumor mutational burden (TMB) as a biomarker of response to immunotherapy in small cell lung cancer

Yanis Boumber  1   2   3
Affiliations
Editorial

Tumor mutational burden (TMB) as a biomarker of response to immunotherapy in small cell lung cancer

Yanis Boumber. J Thorac Dis. 2018 Aug.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The author has served on advisory boards of Astra Zeneca, Boehringer Ingelheim, Bristol-Meyers Squibb, Caris Life Sciences, Novartis and Takeda.

Figures

Figure 1
Figure 1
Small cell lung cancer (SCLC) cell mutational burden, and PD-1 and CTLA-4 inhibitor response. 1, mutations in SCLC cells, mostly related to smoking, generate neo-antigens; 2, neo-antigens are expressed on the cancer cell surface; 3, antigen presenting cells (APCs) recognize neo-antigens, and present them to CD8+ T-cells, inducing cytotoxic T-cell responses; 4, cytotoxic CD8+ T-cell activation occurs, resulting in robust neo-antigen-dependent tumor cell death. Combination of two checkpoint inhibitors is effective against subset of SCLCs with high TMB that reach a threshold for robust CD8+ cytotoxic T-cell activation. B7.1/CD80 and B7.2/CD86 are proteins expressed on APC that bind to CTLA-4 on cytotoxic CD8+ T cells.
See this image and copyright information in PMC

Comment on

References

    1. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12:252-64. 10.1038/nrc3239 - DOI - PMC - PubMed
    1. Wolchok JD, Saenger Y. The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation. Oncologist 2008;13 Suppl 4:2-9. 10.1634/theoncologist.13-S4-2 - DOI - PubMed
    1. Bansal P, Osman D, Gan GN, et al. Recent Advances in Immunotherapy in Metastatic NSCLC. Front Oncol 2016;6:239. - PMC - PubMed
    1. Iwai Y, Hamanishi J, Chamoto K, et al. Cancer immunotherapies targeting the PD-1 signaling pathway. J Biomed Sci 2017;24:26. 10.1186/s12929-017-0329-9 - DOI - PMC - PubMed
    1. Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science 2018;359:1350-5. 10.1126/science.aar4060 - DOI - PMC - PubMed